Key facts
- It has raised $15.8M; the latest was Later Stage VC ($15.8M) in Apr 2026.
- Notable investors include European Innovation Council, NATO Innovation Fund, Cedars-Sinai Accelerator, DutchBasecamp, LifeSciences@Work — 7 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for inbiome
- ·The full record, as it builds
Funding rounds
No funding rounds for inbiome are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About inbiome
Developer of molecular technology designed for bacterial diagnosis. The company's main offerings include advanced molecular technology for microbiome analysis, which aids in improving the understanding and diagnostics of bacteria in the human body, enabling clients with correct treatments and minimization of unnecessary complications, costs, and antimicrobial resistance.
- Sector
- Healthcare
- HQ
- Amsterdam, Netherlands
- Employees
- 25
- Website
- inbiome.com/
- Ownership
- Privately Held (backing)
inbiome doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in inbiome shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on inbiome in its N-PORT filings yet. We sweep new filings monthly.